Sarcomatrix Therapeutics To Present Advances In Muscle Disease Drug Development At 2025 BIO CEO & Investor Conference
Sarcomatrix Therapeutics, Corp Logo Company Prepares for Phase 1 Clinical Trials of Lead Candidate S-969 in 2025 Our robust preclin ...